Theravance Biopharma announced mixed results from a study evaluating the use of ampreloxetine to reduce symptomatic neurogenic orthostatis hypotension (nOH).

Shares of Theravance Biopharma rapidly declined after the company announced a Phase III cardiac drug failed to meet the study’s primary endpoint and a significant shift in its R&D efforts that resulted in a 75 percent staff termination.

George Medicines announced the initiation of two Phase III trials investigating the late-stage drug development company’s proprietary triple combination candidate, GMRx2, as a first-line treatment for hypertension.

The European Commission approved La Jolla Pharmaceutical Company’s Giapreza (angiotensin II) for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies.